Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE)

Overview of attention for article published in Breast Cancer Research, January 2023

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (77th percentile)
Above-average Attention Score compared to outputs of the same age and source (60th percentile)

So far, Dimensions has found 16 publications that cite this research output.

Article in Nature Reviews Clinical Oncology (September 2024)

Article in Nature Communications (July 2024)

Article in Pharmaceuticals (June 2024)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.